Author

G. L. Dornan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

A. Schuetz· 1 shared C. J. Powell· 1 shared C. Seyffarth· 1 shared D. Fiedler· 1 shared J. E. Burke· 1 shared J. P. von Kries· 1 shared J. T. Stariha· 1 shared M. J. Boulanger· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Schuetz

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivApr 26, 2023

An unconventional gatekeeper mutation sensitizes inositol hexakisphosphate kinases to an allosteric inhibitor

T. Aguirre, G. L. Dornan, S. Hostachy…·D. Fiedler

The paper identifies FMP-201300 as a potent and selective inhibitor for IP6K1 and IP6K2 with a valine gatekeeper mutation, revealing an allosteric mechanism of action.

DOI 10.7554/elife.88982

experimental assaydrug response / drug discovery

𝕏 PostBluesky

BiochemistrybioRxivJul 16, 2019

Defining how oncogenic and developmental mutations of PIK3R1 alter the regulation of class IA phosphoinositide 3-kinases

G. L. Dornan, J. T. Stariha, M. K. Rathinawamy…·J. E. Burke

This study investigates how mutations in PIK3R1 affect class IA PI3K regulation, finding that oncogenic mutations hyper-activate p110 while developmental mutations reduce RTK sensitivity.

DOI 10.1016/j.str.2019.11.013

humanexperimental assay

𝕏 PostBluesky